Evidence map›Paper›PMID 39362083›Full record

ArticleBioorganic chemistry2024

Evaluation of expanded 2-aminobenzothiazole library as inhibitors of a model histidine kinase and virulence suppressors in Pseudomonas aeruginosa.

Conrad A Fihn, Hannah K Lembke, Jeffrey Gaulin, Patricia Bouchard, Alex R Villarreal, Mitchell R Penningroth, Kathryn K Crone, Grace A Vogt, Adam J Gilbertsen, Yann Ayotte and 6 more

Abstract read
In one paragraph

Article in Bioorganic chemistry, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Article
  3. Development of covalent inhibitors for bacterial histidine kinases.Chemical communications (Cambridge, England) · 2026
    Article
  4. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

16 authors.

Conrad A FihnDepartment of Medicinal Chemistry, University of Minnesota, 308 Harvard Street SE, Minneapolis, MN 55455, United States.
Hannah K LembkeDepartment of Chemistry, University of Minnesota, 207 Pleasant Street SE, Minneapolis, MN 55454, United States.
Jeffrey GaulinThe Broad Institute of MIT and Harvard, Cambridge, MA 02142, United States.
Patricia BouchardNMX Research and Solution Inc., 500 Cartier Boulevard W., Suite 6000, Laval, Quebec H1Y 2R1, Canada.
Alex R VillarrealDepartment of Microbiology & Immunology, University of Minnesota, 689 23rd Ave SE Minneapolis, MN 55455, United States.
Mitchell R PenningrothDepartment of Microbiology & Immunology, University of Minnesota, 689 23rd Ave SE Minneapolis, MN 55455, United States.
Kathryn K CroneDepartment of Biochemistry, Molecular Biology and Biophysics, University of Minnesota, 321 Church Street SE, Minneapolis, MN 55455, United States.
Grace A VogtDepartment of Microbiology & Immunology, University of Minnesota, 689 23rd Ave SE Minneapolis, MN 55455, United States.
Adam J GilbertsenDepartment of Microbiology & Immunology, University of Minnesota, 689 23rd Ave SE Minneapolis, MN 55455, United States.
Yann AyotteNMX Research and Solution Inc., 500 Cartier Boulevard W., Suite 6000, Laval, Quebec H1Y 2R1, Canada.
Luciana Coutinho de OliveiraNMX Research and Solution Inc., 500 Cartier Boulevard W., Suite 6000, Laval, Quebec H1Y 2R1, Canada.
Michael H Serrano-Wu3 Point Bio LLC, 245 Main Street, Cambridge, MA 02142, United States.
Nathalie DrouinNMX Research and Solution Inc., 500 Cartier Boulevard W., Suite 6000, Laval, Quebec H1Y 2R1, Canada.
Deborah T HungThe Broad Institute of MIT and Harvard, Cambridge, MA 02142, United States.
Ryan C HunterDepartment of Microbiology & Immunology, University of Minnesota, 689 23rd Ave SE Minneapolis, MN 55455, United States.
Erin E CarlsonDepartment of Medicinal Chemistry, University of Minnesota, 308 Harvard Street SE, Minneapolis, MN 55455, United States; Department of Chemistry, University of Minnesota, 207 Pleasant Street SE, Minneapolis, MN 55454, United States; Department of Biochemistry, Molecular Biology and Biophysics, University of Minnesota, 321 Church Street SE, Minneapolis, MN 55455, United States. Electronic address: carlsone@umn.edu.

Funding

TRAINING FOR FUTURE BIOTECHNOLOGY DEVELOPMENTT32GM008347 · NIGMS · UNIVERSITY OF MINNESOTA TWIN CITIES · PI SCHMIDT-DANNERT, CLAUDIA · 1990 to 2021
$11.0M
Chemical Strategies to Map Bacterial Response to Environmental ChangeR35GM153306 · NIGMS · UNIVERSITY OF MINNESOTA · PI Erin Elizabeth Carlson · 2024 to 2026
$1.6M
Discovery of New Antibacterial Targets: Probes and Inhibitors of Histidine Kinase ProteinsR01GM134538 · NIGMS · UNIVERSITY OF MINNESOTA · PI CARLSON, ERIN ELIZABETH · 2020 to 2023
$1.2M
NIGMS NIH HHS R01 GM134538NIGMS NIH HHS R35 GM153306NIGMS NIH HHS T32 GM008347
6 · The paper itself

Abstract

Bacterial resistance to antibiotics is a rapidly increasing threat to human health. New strategies to combat resistant organisms are desperately needed. One potential avenue is targeting two-component systems, which are the main bacterial signal transduction pathways used to regulate development, metabolism, virulence, and antibiotic resistance. These systems consist of a homodimeric membrane-bound sensor histidine kinase, and a cognate effector, the response regulator. Histidine kinases play an essential role in the regulation of multiple virulence mechanisms including toxin production, immune evasion, and antibiotic resistance. Targeting virulence, as opposed to development of bactericidal compounds, could reduce evolutionary pressure for acquired resistance. Additionally, compounds targeting the highly conserved catalytic and adenosine triphosphate-binding (CA) domain have the potential to impair multiple two-component systems that regulate virulence in one or more pathogens. We conducted in vitro structure-activity relationship studies of 2-aminobenzothiazole-based inhibitors designed to target the CA domain. We found that these compounds, which inhibit the model histidine kinase, HK853 from Thermotoga maritima, have anti-virulence activities inPseudomonas aeruginosa, reducing motility phenotypes and toxin production associated with the pathogenic functions of this bacterium.

Indexed as

Anti-Bacterial AgentsHistidine KinaseProtein Kinase InhibitorsPseudomonas aeruginosaBenzothiazolesDose-Response Relationship, DrugMicrobial Sensitivity TestsMolecular StructureSmall Molecule LibrariesStructure-Activity RelationshipVirulenceaminobenzothiazole compoundAnti-Bacterial AgentsBenzothiazolesHistidine KinaseProtein Kinase InhibitorsSmall Molecule LibrariesBacteriaHistidine KinasePseudomonas aeruginosaTwo-Component SystemVirulence

Identifiers

PMID39362083
PMCPMC11614690

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.